Brigrel tablet (Ticagrelor).

• Composition :
  Each tablet contains 60/90 mg of Ticagrelor.
• Indications :
  Indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with Acute coronary syndromes (ACS) unstable angina, non ST elevation Myocardial infarction (STEMI) including patients managed medically, also indicated in those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
• Pharmacodynamics :
  Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor exerts its action via binding to the P2Y12 receptor in a manner distinct from ADP, resulting in a reversible conformational change of the receptor.
• Dosage and administration :
  In the management of ACS, initiate Brigrel treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year, administer 60 mg twice daily. Brigrel can be administered with or without food.
• Contraindications :
  History of intracranial hemorrhage, Active pathological bleeding, Hypersensitivity to ticagrelor or any component of the product
• Precautions and warnings :
  Use Brigrel with a maintenance dose of aspirin of 75-100 mg. Dyspnea was reported more frequently with ticagrelor than with clopidogrel. Dyspnea resulting from ticagrelor is self-limiting.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy category C drug. There are no adequate and well-controlled studies in pregnant women, Nursing women. Safety and effectiveness in pediatric patients have not been established
• Drug interactions :
  Use of ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness of ticagrelor. Strong CYP3A inhibitors or CYP3A inducers- use is avoided concomitantly. Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effect. Monitor digoxin levels.
• Adverse reactions :
  Most common adverse reactions are Bleeding, Dyspnea, diarrhea and dizziness.
• Therapy Area :
  Anti-Platelets